Institute of Psychiatry Psychology Neuroscience, King's College London, London, UK.
OASIS Clinic, SLaM NHS Foundation Trust, London, UK.
Acta Psychiatr Scand. 2016 Sep;134(3):207-24. doi: 10.1111/acps.12619. Epub 2016 Jul 12.
Since the first study published in the Lancet in 1976, structural neuroimaging has been used in psychosis with the promise of imminent clinical utility. The actual impact of structural neuroimaging in psychosis is still unclear.
We present here a critical review of studies involving structural magnetic resonance imaging techniques in patients with psychosis published between 1976 and 2015 in selected journals of relevance for the field. For each study, we extracted summary descriptive variables. Additionally, we qualitatively described the main structural findings of each article in summary notes and we employed a biomarker rating system based on quality of evidence (scored 1-4) and effect size (scored 1-4).
Eighty studies meeting the inclusion criteria were retrieved. The number of studies increased over time, reflecting an increased structural imaging research in psychosis. However, quality of evidence was generally impaired by small samples and unclear biomarker definitions. In particular, there was little attempt of replication of previous findings. The effect sizes ranged from small to modest. No diagnostic or prognostic biomarker for clinical use was identified.
Structural neuroimaging in psychosis research has not yet delivered on the clinical applications that were envisioned.
自 1976 年在《柳叶刀》上发表第一篇研究以来,结构性神经影像学已被用于精神疾病研究,有望很快具有临床实用性。但结构性神经影像学在精神疾病中的实际影响仍不清楚。
我们对 1976 年至 2015 年间在相关领域的选定期刊上发表的涉及精神疾病患者结构性磁共振成像技术的研究进行了批判性回顾。对于每项研究,我们提取了总结性描述变量。此外,我们在总结笔记中定性描述了每篇文章的主要结构发现,并采用了基于证据质量(评分 1-4)和效应大小(评分 1-4)的生物标志物评分系统。
共检索到符合纳入标准的 80 项研究。随着时间的推移,研究数量有所增加,反映了精神疾病结构性影像学研究的增加。然而,证据质量普遍受到样本量小和生物标志物定义不明确的影响。特别是,很少有对先前发现的重复研究。效应大小从小到中等不等。未发现可用于临床的诊断或预后生物标志物。
结构性神经影像学在精神疾病研究中尚未实现预期的临床应用。